Harbour BioMed, a Chinese biopharmaceutical company, completed a Series A+ round of financing.
The round was financed by Chinese PE firm CDH Investments, with participation from Series A round investor Advantech Capital.
The financial details of the deal were not disclosed.
The company intends to use the funds to accelerate its growth, especially the development of multiple clinical programs.
Led by Dr. Jingsong Wang, CEO, Harbour BioMed is a global biopharmaceutical company discovering and developing innovative therapeutics for cancer, with a focus on immuno-oncology, and immunological diseases. The company’s discovery and development programs are built around its two patented transgenic mouse platforms (Harbour Mice) for human antibody discovery. It is building its proprietary pipeline through its innovative internal discovery programs, and through in-licensing clinical stage assets that strategically fit its internal portfolio.
Harbour BioMed also licenses the platforms to companies and academic institutions through its wholly-owned Harbour Antibodies BV subsidiary.
Established in 2016 with $50m A round financing, the company acquired Harbour Antibodies BV and its subsidiaries, one of the few companies that owns technologies for generating fully human monoclonal antibodies, of both conventional as well as heavy chain only form. Current investors of Harbour BioMed include Atlas Venture, Advantech Capital, Legend Capital, CDH Investments and founding team.
Harbour BioMed has headquarters and R&D Centers in China, a Business Operation and Innovation Center in Boston, and an Antibody Technology Innovation Center in Rotterdam, The Netherlands.